GSK plc (NYSE:GSK) Holdings Raised by Cetera Trust Company N.A

Cetera Trust Company N.A raised its stake in shares of GSK plc (NYSE:GSK) by 7.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,590 shares of the pharmaceutical company’s stock after purchasing an additional 485 shares during the period. Cetera Trust Company N.A’s holdings in GSK were worth $223,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in GSK by 33.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,256,320 shares of the pharmaceutical company’s stock valued at $86,875,000 after purchasing an additional 569,614 shares in the last quarter. AE Wealth Management LLC increased its holdings in GSK by 4.3% in the second quarter. AE Wealth Management LLC now owns 19,869 shares of the pharmaceutical company’s stock worth $765,000 after buying an additional 815 shares during the last quarter. Sei Investments Co. raised its holdings in shares of GSK by 3.1% during the 2nd quarter. Sei Investments Co. now owns 831,592 shares of the pharmaceutical company’s stock valued at $32,017,000 after purchasing an additional 24,658 shares in the last quarter. Summit Trail Advisors LLC raised its holdings in GSK by 37.2% during the second quarter. Summit Trail Advisors LLC now owns 7,473 shares of the pharmaceutical company’s stock valued at $290,000 after buying an additional 2,027 shares in the last quarter. Finally, Profund Advisors LLC raised its stake in shares of GSK by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 14,979 shares of the pharmaceutical company’s stock valued at $577,000 after acquiring an additional 433 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

NYSE GSK opened at $33.55 on Wednesday. The firm has a market cap of $69.52 billion, a price-to-earnings ratio of 21.76, a PEG ratio of 1.47 and a beta of 0.63. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The company has a 50 day moving average of $33.93 and a 200-day moving average of $37.90.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were paid a $0.3928 dividend. The ex-dividend date was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.68%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 96.10%.

Analysts Set New Price Targets

GSK has been the subject of a number of research analyst reports. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Seven research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.